The estimated Net Worth of William Roberts is at least 46 百万$ dollars as of 18 September 2013. William Roberts owns over 15,000 units of Regeneron Pharmaceuticals stock worth over 40,685,844$ and over the last 21 years William sold REGN stock worth over 5,270,640$.
Sign up
William Roberts REGN stock SEC Form 4 insiders trading
William has made over 19 trades of the Regeneron Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently William exercised 15,000 units of REGN stock worth 252,000$ on 18 September 2013.
The largest trade William's ever made was exercising 60,000 units of Regeneron Pharmaceuticals stock on 10 January 2012 worth over 1,267,200$. On average, William trades about 10,152 units every 60 days since 2003. As of 18 September 2013 William still owns at least 35,644 units of Regeneron Pharmaceuticals stock.
You can see the complete history of William Roberts stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Regeneron Pharmaceuticals
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over 13,084,686,326$ worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth 2,539,854,760$ . The most active insiders traders include Sanofi、Pharma Ag Novartis、Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of 47,694,347$. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth 381,400$.
What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
What does Regeneron Pharmaceuticals's logo look like?
Complete history of William Roberts stock trades at Regeneron Pharmaceuticals
Regeneron Pharmaceuticals executives and stock owners
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:
-
P. Roy Vagelos,
Chairman of the Board, Director -
Leonard Schleifer,
President, Chief Executive Officer, Director -
George Yancopoulos,
President, Chief Scientific Officer, Director -
Marion McCourt,
Senior Vice President - Commercial -
Andrew Murphy,
Executive Vice President - Research -
Neil Stahl,
Executive Vice President - Research and Development -
Robert Landry,
Chief Financial Officer, Executive Vice President - Finance -
Daniel Van Plew,
Executive Vice President, General Manager - Industrial Operations and Product Supply -
Dr. George D. Yancopoulos M.D., Ph.D.,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Dr. Leonard S. Schleifer M.D., Ph.D.,
Founder, Pres, CEO & Director -
Dr. George D. Yancopoulos,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Robert E. Landry Jr.,
Exec. VP of Fin. & CFO -
Daniel P. Van Plew,
Exec. VP and GM of Industrial Operations & Product Supply -
Joseph J. LaRosa,
Exec. VP, Gen. Counsel & Sec. -
Dr. Andrew J. Murphy,
Exec. VP of Research -
Arthur Ryan,
Independent Director -
George Sing,
Independent Director -
Christine Poon,
Independent Director -
Michael Brown,
Independent Director -
Huda Zoghbi,
Independent Director -
Joseph Goldstein,
Independent Director -
Bonnie Bassler,
Independent Director -
N. Anthony Coles,
Independent Director -
Marc Tessier-Lavigne,
Independent Director -
Christopher Fenimore,
Vice President, Controller -
Joseph LaRosa,
Executive Vice President, General Counsel, Secretary -
Justin Holko,
VP of Investor Relations -
Bob McCowan,
Sr. VP of IT & Chief Information Officer -
Gerald Underwood,
Sr. VP of Technical Operations -
Christopher R. Fenimore,
Sr. VP, Head of Accounting & Controller -
Patrice Gilooly,
Sr. VP of Quality Assurance & Operations -
Charles A Baker,
Director -
Michael S Aberman,
SVP Strategy Investor Relation -
Sanofi,
-
Robert J Terifay,
EVP Commercial -
Alfred G Gilman,
Director -
Robert Alexander Ingram,
Director -
Eric M Shooter,
Director -
Murray A Goldberg,
SVP Administration & Asst Secr -
Stuart Kolinski,
SVP General Counsel and Secret -
Amerique Du Nord S.N.C. San...,
-
Peter Dworkin,
VP Investor Relations & Commun -
Randall Rupp,
SVP, Manufuring Operations -
Pharma Ag Novartis,
10% owner -
Hans Peter Guler,
VP Clinical Programs -
William Roberts,
VP Reg Dev & Med Safety -
Peter Powchik,
SVP Clinical Development & Reg -
Douglas S Mc Corkle,
VP Controller and Asst Treasur -
Craig B. Thompson,
Director -
Kathryn Guarini,
Director -
David P Schenkein,
Director -
Jason Pitofsky,
VP Controller